MoonLake Immunotherapeutics downgraded by BTIG Research
$MLTX
Biotechnology: Pharmaceutical Preparations
Health Care
BTIG Research downgraded MoonLake Immunotherapeutics from Buy to Neutral
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/2/2025 | Buy → Neutral | H.C. Wainwright | |
| 10/1/2025 | $7.00 | Buy → Neutral | Goldman |
| 9/30/2025 | $2.00 | Outperform → Underperform | Wolfe Research |
| 9/30/2025 | $5.00 | Buy → Neutral | Citigroup |
| 9/29/2025 | $8.00 | Buy → Hold | Jefferies |
| 9/29/2025 | Buy → Neutral | BTIG Research | |
| 9/29/2025 | $10.00 | Outperform → Sector Perform | RBC Capital Mkts |
| 9/29/2025 | $13.00 | Buy → Hold | Stifel |
VELA-1 and VELA-2 are two identical trials to evaluate the efficacy and safety of sonelokimab in adult participants with moderate to severe hidradenitis suppurativa (HS) and the first Phase 3 program using the higher clinical response level of HS Clinical Response (HiSCR) 75 as primary endpoint at week 16Data was analyzed, as per protocol and in accordance with regulatory agency feedback, using a composite strategy as the primary analysis and a treatment policy strategy to test the robustness of the results: difference between the two methods relates to the statistical handling of intercurrent eventsIn the combined VELA program, patients treated with sonelokimab experienced a clinically
Phase 3 VELA program in hidradenitis suppurativa (HS) on track for an expected primary endpoint readout around September 2025 and an expected submission of a Biologic License Application (BLA) in the United States in mid-2026Other clinical trials of sonelokimab in palmoplantar pustulosis (PPP), axial spondyloarthritis (axSpA), psoriatic arthritis (PsA) and adolescent HS progressing well and expected to support a catalyst-rich roadmap over the next 12 monthsEnded the second quarter with $425.1 million in cash, cash equivalents and short-term marketable debt securities with up to an additional $425 million in non-dilutive funds remaining accessible through previously announced debt-facility Z
MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update Continued to make significant progress with the development of the Nanobody® sonelokimab across portfolio of indications, including Phase 3 studies in hidradenitis suppurativa (HS), psoriatic Arthritis (PsA) and adolescent HS, as well as Phase 2 studies in palmoplantar pustulosis (PPP) and axial spondyloarthritis (axSpA)Announced completion of enrollment of patients in the Phase 3 program in HS (the VELA program) and disclosed baseline characteristics, replicating the Phase 2 MIRA trialPresented an interim readout of the Phase 2 LEDA study in PPP, highlighting the potential of sonelokimab
H.C. Wainwright downgraded MoonLake Immunotherapeutics from Buy to Neutral
Goldman downgraded MoonLake Immunotherapeutics from Buy to Neutral and set a new price target of $7.00
Wolfe Research downgraded MoonLake Immunotherapeutics from Outperform to Underperform and set a new price target of $2.00
4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
SCHEDULE 13G/A - MoonLake Immunotherapeutics (0001821586) (Subject)
8-K - MoonLake Immunotherapeutics (0001821586) (Filer)
SCHEDULE 13G - MoonLake Immunotherapeutics (0001821586) (Subject)
4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
SC 13G/A - MoonLake Immunotherapeutics (0001821586) (Subject)
SC 13D/A - MoonLake Immunotherapeutics (0001821586) (Subject)
SC 13D/A - MoonLake Immunotherapeutics (0001821586) (Subject)
Phase 3 VELA program in hidradenitis suppurativa (HS) on track for an expected primary endpoint readout around September 2025 and an expected submission of a Biologic License Application (BLA) in the United States in mid-2026Other clinical trials of sonelokimab in palmoplantar pustulosis (PPP), axial spondyloarthritis (axSpA), psoriatic arthritis (PsA) and adolescent HS progressing well and expected to support a catalyst-rich roadmap over the next 12 monthsEnded the second quarter with $425.1 million in cash, cash equivalents and short-term marketable debt securities with up to an additional $425 million in non-dilutive funds remaining accessible through previously announced debt-facility Z
MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update Continued to make significant progress with the development of the Nanobody® sonelokimab across portfolio of indications, including Phase 3 studies in hidradenitis suppurativa (HS), psoriatic Arthritis (PsA) and adolescent HS, as well as Phase 2 studies in palmoplantar pustulosis (PPP) and axial spondyloarthritis (axSpA)Announced completion of enrollment of patients in the Phase 3 program in HS (the VELA program) and disclosed baseline characteristics, replicating the Phase 2 MIRA trialPresented an interim readout of the Phase 2 LEDA study in PPP, highlighting the potential of sonelokimab
Initiated the Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (HS) and the Phase 3 IZAR program in patients with active psoriatic arthritis (PsA) following positive FDA and EMA regulatory feedback, continuing to support a potential best-in-class profile across two key indicationsInitiated three new trials in the beginning of 2025 with the Nanobody® sonelokimab: Phase 3 VELA-TEEN trial in adolescent hidradenitis suppurativa (HS), Phase 2 LEDA trial in palmoplantar pustulosis (PPP) and Phase 2 S-OLARIS trial in axial spondyloarthritis (axSpA)Signed a three-year technology partnership with Komodo Health to advance research on inflam